Tissue Tranglutaminase Regulates Interactions Between Ovarian Cancer Stem Cells and the Tumor Niche

Overview

Journal Cancer Res

Specialty Oncology

Date 2018 Mar 8

PMID 29510995

Citations 36

Authors

Salvatore Condello

Livia Sima

Cristina Ivan

Horacio Cardenas

Gary Schiltz

Rama K Mishra

Daniela Matei

Affiliations

Soon will be listed here.

Abstract

Cancer progression and recurrence are linked to a rare population of cancer stem cells (CSC). Here, we hypothesized that interactions with the extracellular matrix drive CSC proliferation and tumor-initiating capacity and investigated the functions of scaffold protein tissue transglutaminase (TG2) in ovarian CSC. Complexes formed by TG2, fibronectin (FN), and integrin β1 were enriched in ovarian CSC and detectable in tumors. A function-inhibiting antibody against the TG2 FN-binding domain suppressed complex formation, CSC proliferation as spheroids, tumor-initiating capacity, and stemness-associated Wnt/β-catenin signaling. Disruption of the interaction between TG2 and FN also blocked spheroid formation and the response to Wnt ligands. TG2 and the Wnt receptor Frizzled 7 (Fzd7) form a complex in cancer cells and tumors, leading to Wnt pathway activation. Protein docking and peptide inhibition demonstrate that the interaction between TG2 and Fzd7 overlaps with the FN-binding domain of TG2. These results support a new function of TG2 in ovarian CSC, linked to spheroid proliferation and tumor-initiating capacity and mediated through direct interactions with Fzd7. We propose this complex as a new stem cell target. These findings reveal a new mechanism by which ovarian CSCs interact with the tumor microenvironment, promoting cell proliferation and tumor initiation. .

Citing Articles

Beyond tumor‑associated macrophages involved in spheroid formation and dissemination: Novel insights for ovarian cancer therapy (Review).

Liu Y, Xiao H, Zeng H, Xiang Y Int J Oncol. 2024; 65(6).

PMID: 39513610 PMC: 11575928. DOI: 10.3892/ijo.2024.5705.

Thermo-Responsive Hydrogel Based on Lung Decellularized Extracellular Matrix for 3D Culture Model to Enhance Cancer Stem Cell Characteristics.

Chen L, Li F, Li R, Zheng K, Zhang X, Ma H Molecules. 2024; 29(18).

PMID: 39339380 PMC: 11433703. DOI: 10.3390/molecules29184385.

Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.

Atwani R, Nagare R, Rogers A, Prasad M, Lazar V, Sandusky G J Exp Clin Cancer Res. 2024; 43(1):156.

PMID: 38822429 PMC: 11143768. DOI: 10.1186/s13046-024-03083-y.

The Role of Transglutaminase 2 in Cancer: An Update.

Zaltron E, Vianello F, Ruzza A, Palazzo A, Brillo V, Celotti I Int J Mol Sci. 2024; 25(5).

PMID: 38474044 PMC: 10931703. DOI: 10.3390/ijms25052797.

Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling.

Fang Y, Xiao X, Wang J, Dasari S, Pepin D, Nephew K NPJ Precis Oncol. 2024; 8(1):7.

PMID: 38191909 PMC: 10774407. DOI: 10.1038/s41698-023-00495-5.

References

Mitra A, Davis D, Tomar S, Roy L, Gurler H, Xie J . In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol. 2015; 138(2):372-7. PMC: 4528621. DOI: 10.1016/j.ygyno.2015.05.040. View

Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius K, Jarvius J . Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006; 3(12):995-1000. DOI: 10.1038/nmeth947. View

Jacobson M, Pincus D, Rapp C, Day T, Honig B, Shaw D . A hierarchical approach to all-atom protein loop prediction. Proteins. 2004; 55(2):351-67. DOI: 10.1002/prot.10613. View

Kerr C, Szmacinski H, Fisher M, Nance B, Lakowicz J, Akbar A . Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. Oncogene. 2016; 36(21):2981-2990. PMC: 5444990. DOI: 10.1038/onc.2016.452. View

Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan Y . FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011; 30(43):4437-46. DOI: 10.1038/onc.2011.145. View

Lawrenson K, Notaridou M, Lee N, Benjamin E, Jacobs I, Jones C . In vitro three-dimensional modeling of fallopian tube secretory epithelial cells. BMC Cell Biol. 2013; 14:43. PMC: 3849984. DOI: 10.1186/1471-2121-14-43. View

Yakubov B, Chen L, Belkin A, Zhang S, Chelladurai B, Zhang Z . Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction. PLoS One. 2014; 9(2):e89285. PMC: 3930694. DOI: 10.1371/journal.pone.0089285. View

Cao L, Petrusca D, Satpathy M, Nakshatri H, Petrache I, Matei D . Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008; 29(10):1893-900. PMC: 2556973. DOI: 10.1093/carcin/bgn158. View

Merle P, Kim M, Herrmann M, Gupte A, Lefrancois L, Califano S . Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol. 2005; 43(5):854-62. DOI: 10.1016/j.jhep.2005.05.018. View

10.

Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K . Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One. 2011; 6(6):e20701. PMC: 3110765. DOI: 10.1371/journal.pone.0020701. View

11.

Lengyel E . Ovarian cancer development and metastasis. Am J Pathol. 2010; 177(3):1053-64. PMC: 2928939. DOI: 10.2353/ajpath.2010.100105. View

12.

Zhang S, Balch C, Chan M, Lai H, Matei D, Schilder J . Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311-20. PMC: 2553722. DOI: 10.1158/0008-5472.CAN-08-0364. View

13.

Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H . Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res. 2007; 67(15):7194-202. DOI: 10.1158/0008-5472.CAN-07-0307. View

14.

Verma A, Wang H, Manavathi B, Fok J, Mann A, Kumar R . Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 2006; 66(21):10525-33. DOI: 10.1158/0008-5472.CAN-06-2387. View

15.

Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley T . Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells. Cell Stem Cell. 2017; 20(3):303-314.e5. PMC: 5337165. DOI: 10.1016/j.stem.2016.11.004. View

16.

Chuang G, Kozakov D, Brenke R, Comeau S, Vajda S . DARS (Decoys As the Reference State) potentials for protein-protein docking. Biophys J. 2008; 95(9):4217-27. PMC: 2567923. DOI: 10.1529/biophysj.108.135814. View

17.

Condello S, Morgan C, Nagdas S, Cao L, Turek J, Hurley T . β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene. 2014; 34(18):2297-308. PMC: 4275429. DOI: 10.1038/onc.2014.178. View

18.

Mann A, Verma A, Sethi G, Manavathi B, Wang H, Fok J . Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res. 2006; 66(17):8788-95. DOI: 10.1158/0008-5472.CAN-06-1457. View

19.

Faverman L, Mikhaylova L, Malmquist J, Nurminskaya M . Extracellular transglutaminase 2 activates beta-catenin signaling in calcifying vascular smooth muscle cells. FEBS Lett. 2008; 582(10):1552-7. DOI: 10.1016/j.febslet.2008.03.053. View

20.

Deasey S, Nurminsky D, Shanmugasundaram S, Lima F, Nurminskaya M . Transglutaminase 2 as a novel activator of LRP6/β-catenin signaling. Cell Signal. 2013; 25(12):2646-51. PMC: 3881002. DOI: 10.1016/j.cellsig.2013.08.016. View